Prospective Grant of Exclusive License: P2X7: Receptor Antagonists; Correction

---
identifier: "/us/fr/02-23333"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Prospective Grant of Exclusive License: P2X7: Receptor Antagonists; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "02-23333"
section_name: "Prospective Grant of Exclusive License: P2X7: Receptor Antagonists; Correction"
positive_law: false
currency: "2002-09-13"
last_updated: "2002-09-13"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "02-23333"
document_type: "notice"
publication_date: "2002-09-13"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "67 FR 58066"
fr_volume: 67
comments_close_date: "2002-12-12"
---


#  Prospective Grant of Exclusive License: P2X
                    7
                    : Receptor Antagonists; Correction

A notice published in the August 29, 2002 *Federal Register* —announcing the prospective grant of an exclusive license for the use of P2X <sub>7</sub> receptor antagonists (67 FR 55415)—incorrectly listed the receipt date for comments/license applications as “October 28, 2002” under the *DATES* section. This notice serves to correct the date to reflect a 90-day review period rather than a 60-day review period. To allow interested parties adequate time to respond, NIH is publishing this notice to amend the *DATES* : section to read: “Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 12, 2002, will be considered.”

Dated: September 3, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.